公开(公告)号：US20240343798A1

公开(公告)日：2024-10-17

申请号：US18682489

申请日：2022-08-09

Applicant: GV20 Therapeutics LLC ,  Shanghai XunBaiHui Biotechnology Co., LTD.

Inventor： Tengfei Xiao ,  Xihao Hu ,  Xiaole Shirley Liu

IPC: C07K16/28 ,  A61K39/00 ,  A61K45/06 ,  A61P35/04 ,  G01N33/50 ,  G01N33/574 ,  G01N33/68

CPC classification number: C07K16/2803 ,  A61K45/06 ,  A61P35/04 ,  G01N33/5023 ,  G01N33/57492 ,  G01N33/6854 ,  A61K2039/505 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92 ,  G01N2333/70503

Abstract: The present invention provides methods and compositions for treating a cancer, and/or an autoimmune disease, by modulating the expression and/or activity of IGSF8 and its binding ligands. The pharmaceutical compositions may include, but are not limited to, antibodies that specifically bind human IGSF8, and have an activity of inhibiting IGSF8-mediated immunosuppression in a subject in need thereof.

公开(公告)号：US20230056288A1

公开(公告)日：2023-02-23

申请号：US17789079

申请日：2020-12-24

Applicant: Xiaole Liu ,  Shanghai XBH Biotechnology Co., LTD. ,  GV20 Therapeutics LLC

Inventor： Xiaole Liu ,  Xihao Hu ,  Tengfei Xiao

IPC: C07K16/28 ,  A61P35/00

Abstract: Methods and compositions are provided. The methods and compositions are used for treating a cancer, and/or an autoimmune disease, by modulating the expression and/or activity of IGSF8 and its binding ligands. The pharmaceutical compositions may include, but are not limited to, antibodies that specifically bind human IGSF8, and have an activity of inhibiting IGSF8-mediated immunosuppression in a subject in need thereof.